Photo of Iñigo Landa, PhD

Iñigo Landa, PhD

Brigham And Women's Hospital

Brigham And Women's Hospital
Phone: (617) 525-5153


ilanda@bwh.harvard.edu

Photo of Iñigo Landa, PhD

Brigham And Women's Hospital
Phone: (617) 525-5153


ilanda@bwh.harvard.edu

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Iñigo Landa, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Iñigo Landa, PhD

Brigham And Women's Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Brigham and Women's Hospital, Harvard Medical School
  • Associate Scientist, Medicine, Brigham And Women's Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My lab studies basic and translational aspects of thyroid cancer genetics and biology. We are particularly interested in elucidating the biological mechanisms of specific genomic alterations in thyroid cancer evolution and disease progression, with a focus on the roles of the non-coding genome and transcriptional deregulation. To this end, we employ a variety of techniques in human samples, cancer cell systems and animal models.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Leandro-García LJ, Landa I. Mechanistic Insights of Thyroid Cancer Progression. Endocrinology 2023. PubMed
  • Landa I, Thornton CE, Xu B, Haase J, Krishnamoorthy GP, Hao J, Knauf JA, Herbert ZT, Martínez P, Blasco MA, Ghossein R, Fagin JA. Telomerase upregulation induces progression of mouse BrafV600E-driven thyroid cancers and triggers non-telomeric effects. Mol Cancer Res 2023. PubMed
  • Fagin JA, Krishnamoorthy GP, Landa I. Pathogenesis of cancers derived from thyroid follicular cells. Nat Rev Cancer 2023. PubMed
  • Landa I. InTERTwined: how promoter mutations impact BRAF-driven thyroid cancers. Curr Opin Endocr Metab Res 2023. PubMed
  • Bikas A, Wong K, Pappa T, Ahmadi S, Wakefield CB, Marqusee E, Xiang P, Altshuler B, Haase J, Barletta JA, Landa I, Alexander EK. Papillary Thyroid Carcinomas with Tall Cell Features: An Intermediate Entity Between Classic and Tall Cell Subtypes. Thyroid 2023; 33:697-704. PubMed
  • Bikas A, Ahmadi S, Pappa T, Marqusee E, Wong K, Nehs MA, Cho NL, Haase J, Doherty GM, Sehgal K, Barletta JA, Alexander EK, Landa I. Additional Oncogenic Alterations in RAS-Driven Differentiated Thyroid Cancers Associate with Worse Clinicopathologic Outcomes. Clin Cancer Res 2023. PubMed
  • Landa I, Thornton CE, Xu B, Haase J, Krishnamoorthy GP, Hao J, Knauf JA, Herbert ZT, Blasco MA, Ghossein R, Fagin JA. Telomerase reactivation induces progression of mouse Braf -driven thyroid cancers without telomere lengthening. bioRxiv 2023. PubMed
  • Xiang P, Ahmadi S, Coleman A, West W, Lobon I, Bikas A, Landa I, Marqusee E, Kim M, Alexander EK, Pappa T. Identifying and Predicting diverse patterns of Benign Nodule Growth. J Clin Endocrinol Metab 2023. PubMed
  • Landa I. Advances in Thyroid Carcinoma. Cancers (Basel) 2022. PubMed
  • Zhao B, Aggarwal A, Im SY, Viswanathan K, Landa I, Nehs MA. Effect of Lactate Export Inhibition on Anaplastic Thyroid Cancer Growth and Metabolism. J Am Coll Surg 2022; 234:1044-1050. PubMed
  • Ahmadi S, Coleman A, de Morais NS, Landa I, Pappa T, Kang A, Kim MI, Marqusee E, Alexander EK. Clinical experience following implementation of routine SPECT-CT imaging following 131-iodine administration for thyroid cancer. Endocr Connect 2022. PubMed
  • Pappa T, Ahmadi S, Bikas A, Hwang S, Coleman A, Lobon I, Xiang PP, Kim M, Marqusee E, Richman DM, Durfee SM, Asch EH, Benson CB, Frates MC, Landa I, Alexander EK. Thyroid nodule shape independently predicts risk of malignancy. J Clin Endocrinol Metab 2022. PubMed
  • Xu B, Zhang L, Setoodeh R, Mohanty AS, Landa I, Balzer B, Tiedje V, Ganly I, Dogan S, Fagin JA, Ghossein R. Prolonged survival of anaplastic thyroid carcinoma is associated with resectability, low tumor-infiltrating neutrophils/myeloid-derived suppressor cells, and low peripheral neutrophil-to-lymphocyte ratio. 2022. PubMed
  • Thornton CEM, Hao J, Tamarapu PP, Landa I. Multiple ETS Factors Participate in the Transcriptional Control of Mutant Promoter in Thyroid Cancers. Cancers (Basel) 2022. PubMed
  • Ahmadi S, Pappa T, Kang AS, Coleman AK, Landa I, Marqusee E, Kim M, Angell TE, Alexander EK. Point of Care Measurement of Body Mass Index and Thyroid Nodule Malignancy Risk Assessment. Front Endocrinol (Lausanne) 2022; 13:824226. PubMed
  • Ghossein CA, Dogan S, Farhat N, Landa I, Xu B. Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform. Virchows Arch 2021. PubMed
  • Xu B, David J, Dogan S, Landa I, Katabi N, Saliba M, Khimraj A, Sherman EJ, Tuttle RM, Tallini G, Ganly I, Fagin JA, Ghossein RA. Primary high-grade non-anaplastic thyroid carcinoma: a retrospective study of 364 cases. Histopathology 2021. PubMed
  • Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, Barletta JA, Lorch JH, Doherty GM, Lindeman NI, Alexander EK, Landa I. Oncogenic mutations in PI3K/AKT/mTOR pathway effectors associate with worse prognosis in BRAF-driven papillary thyroid cancer patients. Clin Cancer Res 2021. PubMed
  • Landa I. PLEKHS1 mutations in thyroid cancers. Thyroid 2020. PubMed
  • Xu B, Fuchs T, Dogan S, Landa I, Katabi N, Fagin JA, Tuttle RM, Sherman E, Gill AJ, Ghossein R. Dissecting Anaplastic Thyroid Carcinoma: A Comprehensive Clinical, Histologic, Immunophenotypic, and Molecular Study of 360 Cases. Thyroid 2020; 30:1505-1517. PubMed
  • Fletcher A, Read ML, Thornton CEM, Larner DP, Poole VL, Brookes K, Nieto HR, Alshahrani M, Thompson RJ, Lavery GG, Landa I, Fagin JA, Campbell MJ, Boelaert K, Turnell AS, Smith VE, McCabe CJ. Targeting Novel Sodium Iodide Symporter Interactors ADP-Ribosylation Factor 4 and Valosin-Containing Protein Enhances Radioiodine Uptake. Cancer Res 2020; 80:102-115. PubMed
  • Landa I, Knauf JA. Mouse Models as a Tool for Understanding Progression in Braf-Driven Thyroid Cancers. Endocrinol Metab (Seoul) 2019; 34:11-22. PubMed
  • Landa I, Pozdeyev N, Korch C, Marlow LA, Smallridge RC, Copland JA, Henderson YC, Lai SY, Clayman GL, Onoda N, Tan AC, Garcia-Rendueles MER, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies. Clin Cancer Res 2019; 25:3141-3151. PubMed
  • Schweppe RE, Pozdeyev N, Pike LA, Korch C, Zhou Q, Sams SB, Sharma V, Pugazhenthi U, Raeburn C, Albuja-Cruz MB, Reigan P, LaBarbera DV, Landa I, Knauf JA, Fagin JA, Haugen BR. Establishment and Characterization of Four Novel Thyroid Cancer Cell Lines and PDX Models Expressing the RET/PTC1 Rearrangement, BRAFV600E, or RASQ61R as Drivers. Mol Cancer Res 2019; 17:1036-1048. PubMed
  • Landa I, Pozdeyev N, Knauf JA, Haugen BR, Fagin JA, Schweppe RE. Genetics of Human Thyroid Cancer Cell Lines-Response. Clin Cancer Res 2019; 25:6883-6884. PubMed
  • Krishnamoorthy GP, Davidson NR, Leach SD, Zhao Z, Lowe SW, Lee G, Landa I, Nagarajah J, Saqcena M, Singh K, Wendel HG, Dogan S, Tamarapu PP, Blenis J, Ghossein RA, Knauf JA, Rätsch G, Fagin JA. and Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC. 2019; 9:264-281. PubMed
  • Ganly I, Makarov V, Deraje S, Dong Y, Reznik E, Seshan V, Nanjangud G, Eng S, Bose P, Kuo F, Morris LGT, Landa I, Carrillo Albornoz PB, Riaz N, Nikiforov YE, Patel K, Umbricht C, Zeiger M, Kebebew E, Sherman E, Ghossein R, Fagin JA, Chan TA. Integrated Genomic Analysis of Hürthle Cell Cancer Reveals Oncogenic Drivers, Recurrent Mitochondrial Mutations, and Unique Chromosomal Landscapes. Cancer Cell 2018; 34:256-270.e5. PubMed
  • Ibrahimpasic T, Xu B, Landa I, Dogan S, Middha S, Seshan V, Deraje S, Carlson DL, Migliacci J, Knauf JA, Untch B, Berger MF, Morris L, Tuttle RM, Chan T, Fagin JA, Ghossein R, Ganly I. Genomic Alterations in Fatal Forms of Non-Anaplastic Thyroid Cancer: Identification of and as Novel Thyroid Cancer Genes Associated with Tumor Virulence. Clin Cancer Res 2017; 23:5970-5980. PubMed
  • Tuttle RM, Fagin JA, Minkowitz G, Wong RJ, Roman B, Patel S, Untch B, Ganly I, Shaha AR, Shah JP, Pace M, Li D, Bach A, Lin O, Whiting A, Ghossein R, Landa I, Sabra M, Boucai L, Fish S, Morris LGT. Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance. JAMA Otolaryngol Head Neck Surg 2017. PubMed
  • Montero-Conde C, Leandro-Garcia LJ, Chen X, Oler G, Ruiz-Llorente S, Ryder M, Landa I, Sanchez-Vega F, La K, Ghossein RA, Bajorin DF, Knauf JA, Riordan JD, Dupuy AJ, Fagin JA. Transposon mutagenesis identifies chromatin modifiers cooperating with in thyroid tumorigenesis and detects as a cancer gene. Proc Natl Acad Sci U S A 2017; 114:E4951-E4960. PubMed
  • Landa I, Ibrahimpasic T, Boucai L, Sinha R, Knauf JA, Shah RH, Dogan S, Ricarte-Filho JC, Krishnamoorthy GP, Xu B, Schultz N, Berger MF, Sander C, Taylor BS, Ghossein R, Ganly I, Fagin JA. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers. J Clin Invest 2016; 126:1052-66. PubMed
  • Garcia-Rendueles ME, Ricarte-Filho JC, Untch BR, Landa I, Knauf JA, Voza F, Smith VE, Ganly I, Taylor BS, Persaud Y, Oler G, Fang Y, Jhanwar SC, Viale A, Heguy A, Huberman KH, Giancotti F, Ghossein R, Fagin JA. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition. 2015; 5:1178-93. PubMed
  • Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, Wong EW, Hu W, Scott SN, Shah RH, Landa I, Button J, Lailler N, Sboner A, Gao D, Murphy DA, Cao Z, Shukla S, Hollmann TJ, Wang L, Borsu L, Merghoub T, Schwartz GK, Postow MA, Ariyan CE, Fagin JA, Zheng D, Ladanyi M, Busam KJ, Berger MF, Chen Y, Chi P. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 2015; 526:453-7. PubMed
  • Mancikova V, Cruz R, Inglada-Pérez L, Fernández-Rozadilla C, Landa I, Cameselle-Teijeiro J, Celeiro C, Pastor S, Velázquez A, Marcos R, Andía V, Álvarez-Escolá C, Meoro A, Schiavi F, Opocher G, Quintela I, Ansede-Bermejo J, Ruiz-Ponte C, Santisteban P, Robledo M, Carracedo A. Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations. Int. J. Cancer 2015; 137:1870-8. PubMed
  • Gild ML, Landa I, Ryder M, Ghossein RA, Knauf JA, Fagin JA. Targeting mTOR in RET mutant medullary and differentiated thyroid cancer cells. Endocr. Relat. Cancer 2013; 20:659-67. PubMed
  • Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA, Fagin JA. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab 2013; 98:E1562-6. PubMed
  • Maliszewska A, Leandro-Garcia LJ, Castelblanco E, Macià A, de Cubas A, Goméz-López G, Inglada-Pérez L, Álvarez-Escolá C, De la Vega L, Letón R, Gómez-Graña Á, Landa I, Cascón A, Rodríguez-Antona C, Borrego S, Zane M, Schiavi F, Merante-Boschin I, Pelizzo MR, Pisano DG, Opocher G, Matias-Guiu X, Encinas M, Robledo M. Differential gene expression of medullary thyroid carcinoma reveals specific markers associated with genetic conditions. Am J Pathol 2013; 182:350-62. PubMed
  • Landa I, Boullosa C, Inglada-Pérez L, Sastre-Perona A, Pastor S, Velázquez A, Mancikova V, Ruiz-Llorente S, Schiavi F, Marcos R, Malats N, Opocher G, Diaz-Uriarte R, Santisteban P, Valencia A, Robledo M. An epistatic interaction between the PAX8 and STK17B genes in papillary thyroid cancer susceptibility. PLoS ONE 2013; 8:e74765. PubMed
  • Leandro-García LJ, Leskelä S, Inglada-Pérez L, Landa I, de Cubas AA, Maliszewska A, Comino-Méndez I, Letón R, Gómez-Graña Á, Torres R, Ramírez JC, Álvarez S, Rivera J, Martínez C, Lozano ML, Cascón A, Robledo M, Rodríguez-Antona C. Hematologic β-tubulin VI isoform exhibits genetic variability that influences paclitaxel toxicity. Cancer Res 2012; 72:4744-52. PubMed
  • Cascón A, Huarte-Mendicoa CV, Javier Leandro-García L, Letón R, Suela J, Santana A, Costa MB, Comino-Méndez I, Landa I, Sánchez L, Rodríguez-Antona C, Cigudosa JC, Robledo M. Detection of the first gross CDC73 germline deletion in an HPT-JT syndrome family. Genes Chromosomes Cancer 2011; 50:922-9. PubMed
  • Landa I, Robledo M. Association studies in thyroid cancer susceptibility: are we on the right track? J Mol Endocrinol 2011; 47:R43-58. PubMed
  • Comino-Méndez I, Gracia-Aznárez FJ, Schiavi F, Landa I, Leandro-García LJ, Letón R, Honrado E, Ramos-Medina R, Caronia D, Pita G, Gómez-Graña A, de Cubas AA, Inglada-Pérez L, Maliszewska A, Taschin E, Bobisse S, Pica G, Loli P, Hernández-Lavado R, Díaz JA, Gómez-Morales M, González-Neira A, Roncador G, Rodríguez-Antona C, Benítez J, Mannelli M, Opocher G, Robledo M, Cascón A. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet 2011; 43:663-7. PubMed
  • Landa I, Robledo M. Association studies in thyroid cancer susceptibility: are we on the right track? J Mol Endocrinol 2011; 47:R43-58. PubMed
  • López-Jiménez E, Gómez-López G, Leandro-García LJ, Muñoz I, Schiavi F, Montero-Conde C, de Cubas AA, Ramires R, Landa I, Leskelä S, Maliszewska A, Inglada-Pérez L, de la Vega L, Rodríguez-Antona C, Letón R, Bernal C, de Campos JM, Diez-Tascón C, Fraga MF, Boullosa C, Pisano DG, Opocher G, Robledo M, Cascón A. Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 2010; 24:2382-91. PubMed
  • Landa I, Montero-Conde C, Malanga D, De Gisi S, Pita G, Leandro-García LJ, Inglada-Pérez L, Letón R, De Marco C, Rodríguez-Antona C, Viglietto G, Robledo M. Allelic variant at -79 (C>T) in CDKN1B (p27Kip1) confers an increased risk of thyroid cancer and alters mRNA levels. Endocr. Relat. Cancer 2010; 17:317-28. PubMed
  • Leandro-García LJ, Leskelä S, Landa I, Montero-Conde C, López-Jiménez E, Letón R, Cascón A, Robledo M, Rodríguez-Antona C. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton 2010; 67:214-23. PubMed
  • Rodríguez-Antona C, Pallares J, Montero-Conde C, Inglada-Pérez L, Castelblanco E, Landa I, Leskelä S, Leandro-García LJ, López-Jiménez E, Letón R, Cascón A, Lerma E, Martin MC, Carralero MC, Mauricio D, Cigudosa JC, Matias-Guiu X, Robledo M. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis. Endocr. Relat. Cancer 2010; 17:7-16. PubMed
  • Landa I, Ruiz-Llorente S, Montero-Conde C, Inglada-Pérez L, Schiavi F, Leskelä S, Pita G, Milne R, Maravall J, Ramos I, Andía V, Rodríguez-Poyo P, Jara-Albarrán A, Meoro A, del Peso C, Arribas L, Iglesias P, Caballero J, Serrano J, Picó A, Pomares F, Giménez G, López-Mondéjar P, Castello R, Merante-Boschin I, Pelizzo MR, Mauricio D, Opocher G, Rodríguez-Antona C, González-Neira A, Matías-Guiu X, Santisteban P, Robledo M. The variant rs1867277 in FOXE1 gene confers thyroid cancer susceptibility through the recruitment of USF1/USF2 transcription factors. PLoS Genet. 2009; 5:e1000637. PubMed
  • Leandro-García LJ, Leskelä S, Montero-Conde C, Landa I, López-Jimenez E, Letón R, Seeringer A, Kirchheiner J, Cascón A, Robledo M, Rodríguez-Antona C. Determination of CYP2D6 gene copy number by multiplex polymerase chain reaction analysis. Anal Biochem 2009; 389:74-6. PubMed
  • Cascón A, Pita G, Burnichon N, Landa I, López-Jiménez E, Montero-Conde C, Leskelä S, Leandro-García LJ, Letón R, Rodríguez-Antona C, Díaz JA, López-Vidriero E, González-Neira A, Velasco A, Matias-Guiu X, Gimenez-Roqueplo AP, Robledo M. Genetics of pheochromocytoma and paraganglioma in Spanish patients. J Clin Endocrinol Metab 2009; 94:1701-5. PubMed
  • López-Jiménez E, de Campos JM, Kusak EM, Landa I, Leskelä S, Montero-Conde C, Leandro-García LJ, Vallejo LA, Madrigal B, Rodríguez-Antona C, Robledo M, Cascón A. SDHC mutation in an elderly patient without familial antecedents. Clin Endocrinol (Oxf) 2008; 69:906-10. PubMed
  • Ruiz-Llorente S, Montero-Conde C, Milne RL, Moya CM, Cebrián A, Letón R, Cascón A, Mercadillo F, Landa I, Borrego S, Pérez de Nanclares G, Alvarez-Escolá C, Díaz-Pérez JA, Carracedo A, Urioste M, González-Neira A, Benítez J, Santisteban P, Dopazo J, Ponder BA, Robledo M, . Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. Cancer Res 2007; 67:9561-7. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Iñigo Landa, PhD but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members